In a regulatory filing, Axsome Therapeutics (AXSM) provided the following update regarding its liquidity position and relationship with Silicon Valley Bank (SIVB). The company has material cash deposits with both SVB and Citibank (C). Notwithstanding, the company believes that its current cash held at Citibank, along with the remaining committed capital from its $350M term loan facility with Hercules Capital, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. Additionally, the FDIC has announced that it will pay SVB depositors an advance dividend within the next week; this forecast does not take into account such funds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AXSM:
- Axsome Therapeutics price target lowered to $84 from $86 at Mizuho
- Axsome Therapeutics price target lowered to $90 from $105 at Guggenheim
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Axsome Therapeutics expects cash to fund operations into cash flow positivity
- Axsome Therapeutics reports Q4 EPS ($1.41), consnesus ($1.14)